Small Cell Neuroendocrine Tumor of the Urinary System：An Overview of Clinicopathological Characteristics and Diagnosis and Treatment

doi:10.3969/j.issn.1007-9572.2016.32.019

Abstract

Abstract: Neuroendocrine tumor（NET）belongs to a group of heterogeneous tumor，it originates from neuroendocrine system and can occur anywhere on the body，but NET which originates from the urinary system is relatively rare.Small cell NET is a kind of NET with poor differentiation.In this article，the clinicopathological features，diagnosis and differential diagnosis，treatment and prognosis of small cell NET of the urinary system were reviewed，thus the understanding and treatment level of this disease can be improved.

Key words: Carcinoma, neuroendocrine, Urogenital system, Pathology, clinical

摘要： 神经内分泌肿瘤是起源于神经内分泌系统的一组异质性肿瘤群，可发生在身体的各个部位，但原发于泌尿系统的神经内分泌肿瘤较为罕见。而小细胞神经内分泌肿瘤是其中一类分化较差的神经内分泌肿瘤。本文将从临床病理特征、诊断及鉴别诊断、治疗及预后等方面对泌尿系统小细胞神经内分泌肿瘤进行综述，以提高临床对该类肿瘤的认识和诊治水平。

关键词: 癌, 神经内分泌, 泌尿生殖系统, 病理学, 临床

LIU Fei, SHI Jian, YUAN Meng. Small Cell Neuroendocrine Tumor of the Urinary System：An Overview of Clinicopathological Characteristics and Diagnosis and Treatment[J]. Chinese General Practice, 2016, 19(32): 3990-3994.

刘飞, 史健, 袁梦. 泌尿系统小细胞神经内分泌肿瘤的临床病理特征及诊疗概述[J]. 中国全科医学, 2016, 19(32): 3990-3994.

References

［1］RINDI G.The ENETS guidelines：the new TNM classification system［J］.Tumori，2010，96（5）：806-809. ［2］宫惠琳，董炜疆，徐长福，等.21例消化系统神经内分泌癌临床病理回顾性分析［J］.肿瘤防治研究，2004，31（1）：51-53. GONG H L，DONG W J，XU C F，et al.A clinico-pathological retrospective study of neuroendocrine tumors in digestive system［J］.Cancer Research on Prevention and Treatment，2004，31（1）：51-53. ［3］PING J H，CHEN Z X，JIONG Q，et al.Small cell neuroendocrine carcinoma of the ureter：a case report and literature review［J］.Oncol Lett，2014，7（3）：728-730. ［4］CHUANG C K，LIAO S K.A retrospective immunohistochemical and clinicopathological study of small cell carcinomas of the urinary tract［J］.Chang Gung Med J，2003，26（1）：26-33. ［5］KORKMAZ T，SEBER S，YAVUZER D，et al.Primary renal carcinoid：treatment and prognosis［J］.Crit Rev Oncol Hematol，2013，87（3）：256-264. ［6］LEE S Y，HSU H H，LIN H Y，et al.Factors associated with the survival of patients with primary small cell carcinoma of the kidney［J］.Int J Clin Oncol，2013，18（1）：139-147. ［7］LANE B R，CHERY F，JOUR G，et al.Renal neuroendocrine tumours：a clinicopathological study［J］.BJU Int，2007，100（5）：1030-1035. ［8］赵海滨，杨树东，周志华，等.肾原发性神经内分泌癌临床病理观察［J］.诊断病理学杂志，2011，18（2）：121-123. ZHAO H B，YANG S D，ZHOU Z H，et al.Neuroendocrine carcinoma of kindey：a clinicopathologic analysis［J］.Chinese Journal of Diagnostic Pathology，2011，18（2）：121-123. ［9］韩冬艳，奚豪，朱延波，等.肾脏神经内分泌癌1例并文献复习［J］.临床与实验病理学杂志，2011，27（9）：977-979. ［10］聂春兰.肾脏神经内分泌癌1例［J］.临床肿瘤学杂志，2011，16（2）：188-189. ［11］CHEN S Y，DU L D，ZHANG Y H.Pilot study of intravesical instillation of two new generation anthracycline antibiotics in prevention of superficial bladder cancer recurrence［J］.Chin Med J（Engl），2010，123（23）：3422-3426. ［12］LA ROSA S，BERNASCONI B，MICELLO D，et al.Primary small cell neuroendocrine carcinoma of the kidney：morphological，immunohistochemical，ultrastructural，and cytogenetic study of a case and review of the literature［J］.Endocr Pathol，2009，20（1）：24-34. ［13］闫风彩，刘茜，陆江阳.原发性肾小细胞癌1例报告及文献复习［J］.现代泌尿外科杂志，2011，16（4）：359-361. YAN F C，LIU Q，LU J Y.Primary renal small cell carcinoma：a case report and literature review［J］.Journal of Modern Urology，2011，16（4）：359-361. ［14］AHSAINI M，RIYACH O，TAZI M F，et al.Small cell neuroendocrine carcinoma of the urinary tract successfully managed with neoadjuvant chemohtherapy［J］.Case Rep Urol，2013，2013：598325. ［15］JANG H，YUK S M，KIM J O，et al.A rare case of primary malignant small cell carcinoma combined with urothelial cell carcinoma in the ureter［J］.World Journal of Surgical Oncology，2013，11（1）：181. ［16］BRENNAN S M，GREGORY D L，STILLIE A.Should extrapulmonary small cell cancer be managed like small cell lung cancer？［J］.Cancer，2010，116（4）：888-895. ［17］OUZZANE A，CHONEIM T P，UDO K，et al.Small cell carcinoma of the upper urinary tract（UUT-SCC）：report of a rare entity and systematic review of the literature［J］.Cancer Treat Rev，2011，37（5）：366-372. ［18］TERADA T.Primary small cell carcinoma of the ureter：a case report involving immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes［J］.Pathology，2010，42（1）：101-102. ［19］TERADA T.Small cell carcinoma of the oral cavity（cheek mucosa）：a case report with an immunohistochemical and molecular genetic analysis［J］.Int J Clin Exp Pathol，2013，6（4）：780-787. ［20］PANT P M，LOPEZ B A，MONTIRONI R，et al.Small cell carcinoma of the urinary bladder［J］.Histol Histopathol，2010，25（2）：217-221. ［21］LABANARIS A P，ZUGOR V，SMISZEK R，et al.Small cell carcinoma encountered in a urinary bladder diverticulum［J］.Urol J，2009，6（1）：54-56. ［22］ZHAO X，FLYNN E A.Small cell carcinoma of the urinary bladder：a rare，aggressive neuroendocrine malignancy［J］.Arch Path Lab Med，2012，136（11）：1451-1459. ［23］OU W T，LIANG Q L，HUANG X，et al.Small cell carcinoma of the urinary bladder：a case report and review of the literature［J］.Journal of Cancer Research ＆ Therapeutics，2015，5（2）：57-59. ［24］PAUL S，PABLO G，MARUGESAN M，et al.Small cell carcinoma of the bladder［J］.J Urol，2006，176（2）：12-17. ［25］YOSHIDA K，ISHIDA M，KAGOTANI A，et al.Small cell carcinoma of the urinary bladder and prostate：cytological analyses of four cases with emphasis on the usefulness of cytological examination［J］.Oncol Lett，2014，7（2）：369-372. ［26］CHURCH D N，BAHL A.Clinical review-small cell carcinoma of the bladder［J］.Cancer Treat Rev，2006，32（8）：588-593. ［27］赵世明，杨锦建，贾占奎.肾上腺小细胞神经内分泌癌1例报告并文献复习［J］.临床泌尿外科杂志，2011，26（7）：535-536，538. ZHAO S M，YANG J J，JIA Z K.Adrenal small cell neuroendocrine carcinoma：report of 1 case and review of the literature［J］.Journal of Clinical Urology，2011，26（7）：535-536，538. ［28］KOAY E J，TEH B S，PAULINO A C，et al.A surveillance，epidemiology，and end results analysis of small cell carcinoma of the bladder：epidemiology，prognostic variables，and treatment trends［J］.Cancer，2011，117（23）：5325-5333. ［29］俞建军，徐月敏，乔勇，等.肾上腺神经内分泌癌二例报告［J］.中华泌尿外科杂志，2006，27（1）：19. ［30］WANG W，EPSTEIN J I.Small cell carcinoma of the prostate.A morphologic and immunohistochemical study of 95 cases［J］.Am J Surg Pathol，2008，32（1）：65-71. ［31］MONIKA J，ZHAO H Y，HAROLD H，et al.Current and emerging therapies in neuroendocrine tumors：impact of genetic targets on clinical outcomes［J］.Clinical Cancer Drugs，2014，1（1）：28-39. ［32］SUN Y，NIU J Y，HUANG J T.Neuroendocrine differentiation in prostate cancer［J］.Am J Transl Res，2009，1（2）：148-162. ［33］CAPIZZELLO A，PEPONI E，SIMOU N，et al.Pure small cell carcinoma of the prostate：a case report and literature review［J］.Case Rep Oncol，2011，4（1）：88-95. ［34］郝通利，洪宝发，吴意光，等.老年前列腺小细胞神经内分泌癌的临床特点与预后［J］.中华保健医学杂志，2010，12（2）：121-123. HAO T L，HONG B F，WU Y G，et al.Clinical analysis of senile patients with small cell carcinoma of prostate with neuroendocrine differentiation［J］.Chinese Journal of Health Care and Medicine，2010，12（2）：121-123. ［35］ROSA N，MICHAEL S，OLEKSANDR N K，et al.Small cell carcinoma of the prostate［J］.Nat Rev Urol，2014，11（4）：213-219. ［36］UEMURA K I，NAKAGAWA G，CHIKUI K，et al.A useful treatment for patients with advanced mixed-type small cell neuroendocrine carcinoma of the prostate：a case report［J］.Oncol Lett，2013，5（3）：793-796. ［37］邵云，赵坡，李向红.Bcl-2、bax、P53在肺神经内分泌癌中表达的意义［J］.中国肺癌杂志，2006，9（1）：55-59. SHAO Y，ZHAO P，LI X H.Expression and significance of Bcl-2，bax，P53 in neuroendocrine carcinomas of the lung［J］.Chinese Journal of Lung Cancer，2006，9（1）：55-59. ［38］何文志，李兴德，赵瑾.胰腺神经内分泌肿瘤的研究进展［J］.现代肿瘤医学，2015，23（12）：1775-1778. HE W Z，LI X D，ZHAO J.Current management of patients with pancreatic neuroendocrine neoplasms and literature review［J］.Journal of Modern Oncology，2015，23（12）：1775-1778. ［39］YAO J C，SHAH M H，ITO T，et al.Everolimus for advanced pancreatic neuroendocrine tumor［J］.N Engl J Med，2011，364（6）：514-523.

[1]	YANG Haifei, SUN Wu, WU Cheng, REN Wei, LI Rutian. Analysis of Predictors for Immune-related Adverse Events and the Correlation with Efficacy in Progressive Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2026, 29(06): 710-717.
[2]	LEI Chunxin, ZHANG Xiya, ZHANG Yan, CHEN Jiaqi, LIU Zihan, LUO Jing, TAO Qingwen. Clinical Characteristics and Influencing Factors of Primary Sjögren's Disease with Dryness and Blood-stasis Syndrome [J]. Chinese General Practice, 2026, 29(06): 718-725.
[3]	Chinese Sleep Research Society, Sleep Medicine Professional Committee of Guangdong Medical Doctor Association, Pharmacy Administration Committee of Guangdong Province Hospital Association, GUO Junlong, ZHENG Ping, JIA Fujun, LI Xueli, ZHAN Shuqin, WANG Yuanqing, GU Ping, FENG Yuan, MO Liqian, HAO Yongci, ZHENG Shuqiong, ZENG Haimei, ZHANG Bin, LI Yilei. Chinese Expert Consensus on the Clinical Application of Lemborexant [J]. Chinese General Practice, 2026, 29(05): 545-558.
[4]	LIU Yongcheng, LIU Siyu, LIANG Xiaoyu, HAO Xiaopeng, WEI Yue, DONG Guoju. Analysis of Echocardiographic Outcome Measures in Randomized Controlled Trials in Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2025, 28(33): 4140-4147.
[5]	HUANG Zichen, XIA Zhongyuan, ZHI Congcong, CHEN Ying, LIU Ningyuan, LIU Dianlong, ZHENG Lihua. Defining Clinical Queries and Construction of Outcome Indexes in Guidelines on the Diagnosis and Treatment of Anal Fistula by Integrated Traditional Chinese and Western Medicine [J]. Chinese General Practice, 2025, 28(32): 4095-4101.
[6]	ZHI Congcong, CHENG Yicheng, HUANG Zichen, WANG Xiaolong, LI Xue, ZHENG Lihua. Collection and Determination of Clinical Questions and Outcome Indicators Based on the Guidelines for Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Hemorrhoids (2025 Edition) [J]. Chinese General Practice, 2025, 28(32): 4089-4094.
[7]	BAI Jiaxin, CHEN Yu, ZHOU Yiheng, LIU Lidi, YANG Rong, YAO Yi, YUAN Bo, ZHANG Yonggang, LEI Yi, ZENG Rui, JIA Yu, LIAO Xiaoyang. Assessment and Treatment of Early-onset Hypertension: Position Statement of the British and Irish Hypertension Association and Its Implications for Clinical Management of Early-onset Hypertension in China [J]. Chinese General Practice, 2025, 28(30): 3741-3746.
[8]	ZHENG Boyue, FU Jiyi, WU Jiafei, WANG Jun, LI Hui. Study on the Efficacy and Safety of Carfilzomib in the Treatment of Multiple Myeloma [J]. Chinese General Practice, 2025, 28(30): 3806-3814.
[9]	XU Baichuan, WANG Yan, ZHANG Peng, LI Yiting, LIU Feilai, XIE Yang. Research and Analysis of Screening Tools for Chronic Obstructive Pulmonary Disease Comorbidity Lung Cancer [J]. Chinese General Practice, 2025, 28(30): 3847-3852.
[10]	ZHAO Wenwen, LI Nuoya, ZHANG Yali, ZHANG Jinjia, ZHANG Min, LIU Hualei, XI Biao, WANG Rongying. Research on Evaluation of Quality Evaluation System of General Practice Faculty in Standardized Clinical Residency Training Bases (General Hospitals) [J]. Chinese General Practice, 2025, 28(25): 3187-3192.
[11]	ZHAI Jiayan, LU Yuan, PAN Ying, YU Dehua. Experience of Introducing Programmatic Assessment in General Practice Clinical Reasoning Courses from Constructivism Learning Theory [J]. Chinese General Practice, 2025, 28(25): 3193-3199.
[12]	JI Bing, JIANG Dudu, CHEN Chen, ZHENG Yanling, SHI Jianwei, FANG Lizheng, DU Xueping. Constructing a Comprehensive Community Clinical Pathway for Herpes Zoster under Graded Treatment Framework [J]. Chinese General Practice, 2025, 28(25): 3110-3118.
[13]	Chinese Hospital Association, Committee for Healthcare Simulation. Expert Consensus on the Application Technology System Standard of Virtual Simulation for Clinical Practice Skills [J]. Chinese General Practice, 2025, 28(23): 2833-2840.
[14]	ZHU Ting, ZHONG Jinjia, WU Hao, HUANG Yafang. Current Status and Characteristics of Novel Cancer Drugs Approved in China with Clinical Response Rate as a Surrogate Endpoint [J]. Chinese General Practice, 2025, 28(20): 2523-2529.
[15]	JIANG Xiaoman, XU Xinyi, DING Lingyu, GUO Yinning, MIAO Xueyi, CHEN Li, XU Qin. Clinical Characteristics and Correlation between Preoperative Frailty and Metabolic Syndrome among Older Patients with Gastric Cancer [J]. Chinese General Practice, 2025, 28(17): 2134-2141.